^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCB99280

    i
    Other names: INCB99280, INCB099280
    Associations

    News

    Trials
    Company:
    Incyte
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants (clinicaltrials.gov)
    P1, N=7, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    INCB99280
    1m
    Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Abramson Cancer Center at Penn Medicine
    New P1 trial • Pre-transplantation
    |
    INCB99280
    2ms
    A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=145, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Inlyta (axitinib) • INCB99280
    2ms
    A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants (clinicaltrials.gov)
    P1, N=7, Not yet recruiting, Incyte Corporation
    New P1 trial
    |
    INCB99280
    7ms
    A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation (clinicaltrials.gov)
    P1, N=125, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • RAS wild-type • KRAS G12
    |
    Krazati (adagrasib) • INCB99280
    8ms
    A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation (clinicaltrials.gov)
    P1, N=125, Not yet recruiting, Incyte Corporation | .
    New P1 trial • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • RAS wild-type • KRAS G12
    |
    Krazati (adagrasib) • INCB99280
    9ms
    Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    MSI (Microsatellite instability) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2 (Interleukin 2)
    |
    MSI-H/dMMR
    |
    Yervoy (ipilimumab) • INCB99280
    9ms
    A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting
    Checkpoint inhibition • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    PD-L1 IHC 22C3 pharmDx
    |
    INCB99280
    10ms
    A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=145, Not yet recruiting, Incyte Corporation
    New P1/2 trial
    |
    Inlyta (axitinib) • INCB99280
    10ms
    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=203, Recruiting, Incyte Corporation | Trial completion date: Mar 2026 --> Oct 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    INCB99280
    11ms
    Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Incyte Corporation
    New P1 trial • Combination therapy
    |
    MSI (Microsatellite instability) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2 (Interleukin 2)
    |
    MSI-H/dMMR
    |
    Yervoy (ipilimumab) • INCB99280
    11ms
    A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Incyte Corporation
    New P2 trial • Metastases
    |
    INCB99280
    11ms
    A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive (clinicaltrials.gov)
    P2; N=314; Not yet recruiting; Sponsor:Incyte Corporation
    Checkpoint inhibition • New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    PD-L1 IHC 22C3 pharmDx
    |
    INCB99280